Cell & Gene Therapy Bioanalytical Testing Services Market

Cell and gene therapy bioanalytical testing services involve a range of laboratory services that are essential for the development, characterisation, and quality control of cell and gene therapy products. These services include analytical testing, safety assessment, potency determination, and characterisation to ensure the safety, efficacy, and compliance of these advanced therapies.

The global market valuation will rise high at a CAGR of 8% during 2023 – 2030, reaching the revenue of US$0.8 billion till the end of this decade. The demand for bioavailability & bioequivalence studies remains higher, whereas non-clinical products continue to be prominent throughout the period of forecast. By the type of therapy, cell therapy holds the largest share of the market value pie.

Cell and gene therapies are experiencing rapid advancements, with innovative treatments being developed for various diseases, including genetic disorders, cancer, and autoimmune conditions. The growth of this market is also driven by the increasing development and adoption of cell and gene therapies. The rising number of clinical trials, regulatory approvals, and the need for rigorous testing and quality assurance are the key contributing factors.

Challenges include the complexity of testing these novel therapies, the need for standardisation and harmonisation of testing methods, and navigating the evolving regulatory landscape. Additionally, as the field expands, there is a growing need for skilled professionals and advanced technologies to support comprehensive testing services.

KCAS Bioanalytical Services, Laboratory Corporation of America Holdings, Prolytix, Pharmaron, Syneos Health, and Charles River Laboratories are some of the kay industry players leading the cell & gene therapy bioanalytical testing services market.